Monoallelic loss-of-function variants in GSK3B lead to autism and developmental delay
- PMID: 39472663
- DOI: 10.1038/s41380-024-02806-z
Monoallelic loss-of-function variants in GSK3B lead to autism and developmental delay
Abstract
De novo variants adjacent to the canonical splicing sites or in the well-defined splicing-related regions are more likely to impair splicing but remain under-investigated in autism spectrum disorder (ASD). By analyzing large, recent ASD genome sequencing cohorts, we find a significant burden of de novo potential splicing-disrupting variants (PSDVs) in 5048 probands compared to 4090 unaffected siblings. We identified 55 genes with recurrent de novo PSDVs that were highly intolerant to variation. Forty-six of these genes have not been strongly implicated in ASD or other neurodevelopmental disorders previously, including GSK3B. Through international, multicenter collaborations, we assembled genotype and phenotype data for 15 individuals with GSK3B variants and identified common phenotypes including developmental delay, ASD, sleeping disturbance, and aggressive behavior. Using available single-cell transcriptomic data, we show that GSK3B is enriched in dorsal progenitors and intermediate forms of excitatory neurons in the developing brain. We showed that Gsk3b knockdown in mouse excitatory neurons interferes with dendrite arborization and spine maturation which could not be rescued by de novo missense variants identified from affected individuals. In summary, our findings suggest that PSDVs may play an important role in the genetic etiology of ASD and allow for the prioritization of new ASD candidate genes. Importantly, we show that genetic variation resulting in GSK3B loss-of-function can lead to a neurodevelopmental disorder with core features of ASD and developmental delay.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: AB and MMM are employees of GeneDx, Inc. All of the remaining authors declare no conflict of interest. Ethics approval and consent to participate: We strictly follow the Guidelines for Clinical Laboratory Biosafety. All of the experimental procedures involving animals were conducted in accordance with the Institutional Animal Care guidelines of Central South University. All cell lines were verified for authenticity. All patient consents were obtained from study participants or their parents or legal guardians, in line with local institutional review board (IRB) requirements at the time of collection. The IRB of Central South University approved this study (Registration number: IRB #2022-1-3).
References
-
- Hirota T, King BH. Autism spectrum disorder: a review. JAMA. 2023;329:157–68. - PubMed
-
- Coe BP, Stessman HAF, Sulovari A, Geisheker MR, Bakken TE, Lake AM, et al. Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. Nat Genet. 2019;51:106–16. - PubMed
-
- Matson JL, Shoemaker M. Intellectual disability and its relationship to autism spectrum disorders. Res Dev Disabil. 2009;30:1107–14. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
